Revive extends $650,000 private placement

Executive Summary

• Revive Therapeutics Ltd. has announced an extension of its previously announced private placement offering, allowing for the issuance of up to 30,952,381 units at $0.021 per unit for gross proceeds of up to $650,000.
• The company previously closed a first tranche in early August 2025, issuing 2.9 million units for $60,900, leaving $589,000 available to be raised in subsequent tranches.
• Each unit consists of one common share and one common share purchase warrant, with the warrants exercisable at $0.05 per share for 36 months.

Key Details

• Offering Size: Up to 30,952,381 units.
• Price Per Unit: $0.021 (2.1 cents).
• Total Gross Proceeds Potential: Up to $650,000.
• Previous Tranche (Closed Aug 2025): 2,900,000 units issued at $0.021 per unit, generating $60,900 in gross proceeds.
• Remaining Capacity: $589,000 available for closing additional tranches.
• Security Structure: Each unit comprises one common share and one common share purchase warrant.
• Warrant Terms:
  • Exercise Price: $0.05 per share.
  • Duration: 36 months following closing.
• Pricing Basis: Based on the 20-day volume-weighted average price (VWAP) of shares traded on the Canadian Securities Exchange at the time price protection was obtained.
• Use of Proceeds: Working capital and payment of certain trade payables.
• Closing Conditions: Subject to customary closing conditions; intended to close as soon as practicable.
• Hold Period: All securities subject to a hold period of four months and one day from the date of issuance.

Notable Quotes

• No direct quotes from management were included in the provided text.